Duke Study: Hospital Losses Incurred By CMS Payment For Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
About two years will pass before inpatient costs associated with drug-eluting stents are accurately reflected in Medicare payment for the devices, causing hospital revenue loss in the short term, according to Kevin Schulman, MD, Duke Clinical Research Institute